Table 2.

Prior^† and concomitant iron use (safety analysis set)

	ESA‐Naïve group			ESA‐Converted group
Parameter	Roxadustat 50 mg (n = 6)	Roxadustat 70 mg (n = 7)	All ESA‐Naïve (n = 13)	All ESA‐Converted (n = 43)
Prior oral iron use, n (%)	1 (16.7)	0	1 (7.7)	8 (18.6)
Prior IV iron use, n (%)	0	0	0	1 (2.3)
Concomitant oral iron use, n (%)	2 (33.3)	0	2 (15.4)	11 (25.6)
Concomitant IV iron use, n (%)	0	0	0	1 (2.3)

^†Period between 42 days before prescreening to the end of screening.

ESA, erythropoiesis stimulating agent; IV, intravenous.